Opportunity Information: Apply for RFA HL 24 016
The National Institutes of Health (NIH) funding opportunity RFA-HL-24-016 supports the Molecular Atlas of Lung Development Program (LungMAP) Phase 3 Data Coordinating Center (DCC) through a U24 cooperative agreement mechanism, with clinical trials not allowed. The core purpose of LungMAP is to create a comprehensive, high-resolution molecular and cellular atlas of the human lung that can be used as a widely accessible reference to understand normal lung biology, how the lung develops, and how disease processes disrupt that biology. By building an integrated atlas that links cell types and states to gene expression patterns, spatial (3-dimensional) location, and developmental or pathological trajectories, the program aims to help researchers identify key cellular players, molecular pathways, and potential therapeutic targets relevant to lung diseases.
In practical terms, the LungMAP resource is designed as an open-access platform that brings together multi-scale and high-content data. This includes fine-grained molecular measurements alongside spatial and structural context, allowing users to move from broad tissue architecture down to specific cell populations and their changing states over time or disease progression. The DCC role implied by this announcement is to coordinate, organize, and support the program-wide data ecosystem so that the resulting atlas is coherent, interoperable, and usable by the wider scientific community. Because the award is a cooperative agreement (rather than a standard grant), NIH program staff typically have substantial involvement in coordinating scientific and operational expectations across the consortium, which often includes setting shared standards, timelines, and deliverables for the overall program.
Eligibility details in the notice emphasize domestic participation requirements while still allowing certain international elements under NIH policy. Foreign institutions (non-U.S. entities) are not eligible to apply as applicants. However, non-domestic components of U.S. organizations may be eligible, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed. The opportunity also lists small businesses among eligible applicant types in the provided source details, indicating that qualifying small business entities can be applicants if they meet NIH and FOA-specific requirements.
Key administrative details from the opportunity listing include an original application due date of October 27, 2023, an award ceiling of $1,260,000, and an NIH health-related activity category under CFDA (Assistance Listing) number 93.838. The opportunity is categorized as discretionary funding and uses the cooperative agreement funding instrument type. Overall, the announcement is centered on supporting the infrastructure and coordination functions needed to sustain and expand LungMAP Phase 3 as an integrated, high-value, open resource for lung development and disease research.Apply for RFA HL 24 016
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838.
- This funding opportunity was created on 2023-09-06.
- Applicants must submit their applications by 2023-10-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,260,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH RFA-HL-24-016 (LungMAP Phase 3 Data Coordinating Center)
What is the funding opportunity number and program?
This opportunity is NIH RFA-HL-24-016. It supports the Molecular Atlas of Lung Development Program (LungMAP) Phase 3 Data Coordinating Center (DCC).
What is the main purpose of LungMAP?
LungMAP aims to create a comprehensive, high-resolution molecular and cellular atlas of the human lung that serves as a widely accessible reference for understanding normal lung biology, lung development, and how disease processes disrupt that biology.
What is meant by a "molecular and cellular atlas" in this program?
Based on the description provided, the atlas integrates information that links lung cell types and cell states to gene expression patterns, spatial (3-dimensional) location within the lung, and developmental or pathological trajectories. The goal is to allow researchers to connect molecular signatures to where cells are located and how they change over time or during disease.
What types of data does the LungMAP resource bring together?
The LungMAP resource is described as an open-access platform that integrates multi-scale and high-content data, including fine-grained molecular measurements along with spatial and structural context. This is intended to support exploration from overall tissue architecture down to specific cell populations and their changing states over time or disease progression.
What does Phase 3 refer to in this funding opportunity?
The notice specifies support for LungMAP Phase 3, focused on sustaining and expanding the program as an integrated, high-value, open resource for lung development and disease research. The funding specifically targets the Data Coordinating Center role for Phase 3.
What is the role of the Data Coordinating Center (DCC) under this announcement?
The DCC is expected to coordinate, organize, and support the program-wide data ecosystem so the atlas is coherent, interoperable, and usable by the broader scientific community. The emphasis is on infrastructure and coordination functions needed across the consortium.
Is this opportunity intended to support clinical trials?
No. Clinical trials are not allowed under this funding opportunity.
What funding mechanism is used?
The award uses a U24 cooperative agreement mechanism.
What does it mean that this is a cooperative agreement?
The description notes that, because the award is a cooperative agreement rather than a standard grant, NIH program staff typically have substantial involvement in coordinating scientific and operational expectations across the consortium. This often includes setting shared standards, timelines, and deliverables for the overall program.
Who is eligible to apply?
Eligibility emphasizes domestic participation requirements. Foreign institutions (non-U.S. entities) are not eligible to apply as applicants. The notice also indicates small businesses are among eligible applicant types in the provided source details, meaning qualifying small business entities may apply if they meet NIH and FOA-specific requirements.
Are any international components allowed?
Yes, certain international elements are allowed under NIH policy as described in the notice. Non-domestic components of U.S. organizations may be eligible, and foreign components (as defined by NIH in the NIH Grants Policy Statement) are allowed. However, foreign institutions themselves are not eligible as applicants.
What is the application due date listed for this opportunity?
The original application due date listed is October 27, 2023.
What is the maximum award amount (award ceiling)?
The award ceiling listed for this opportunity is $1,260,000.
What is the Assistance Listing (CFDA) number for this opportunity?
The Assistance Listing (CFDA) number provided is 93.838.
How is this funding opportunity categorized?
It is categorized as discretionary funding and uses the cooperative agreement funding instrument type.
What is the intended impact of building this integrated lung atlas?
The program aims to help researchers identify key cellular players, molecular pathways, and potential therapeutic targets relevant to lung diseases by linking cell identity and state to gene expression, spatial location, and developmental or disease trajectories.
What does "open-access platform" mean in the context provided?
The opportunity describes the LungMAP resource as an open-access platform designed to be widely accessible to the scientific community, enabling broad use of the integrated data and reference atlas.
What does "interoperable" imply for the LungMAP data ecosystem?
Within the provided description, interoperability refers to organizing and coordinating the program-wide data ecosystem so that data and resources work together coherently across the consortium and are usable by the wider research community as a unified atlas.
What kinds of program-wide expectations might NIH coordinate under a cooperative agreement?
The notice suggests NIH program staff involvement often includes coordinating shared standards, timelines, and deliverables across the consortium to ensure the overall program produces a coherent and usable atlas resource.
Browse more opportunities from the same category: Health
Next opportunity: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
Previous opportunity: A Consortium for Gut-Brain Communication in Parkinsons Disease (U01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 24 016
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 24 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| High-Priority Behavioral and Social Research Networks??(R24 Clinical Trial Optional) Apply for RFA AG 24 034 Funding Number: RFA AG 24 034 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| State Dementia Care Research Center (U54 Clinical Trial Not Allowed) Apply for RFA AG 24 033 Funding Number: RFA AG 24 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Approaches to Identifying Preteen Suicide Risk and Protective Factors (R01 Clinical Trial Not Allowed) Apply for RFA MH 24 320 Funding Number: RFA MH 24 320 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: The Harmonized Cognitive Assessment Protocol (HCAP) Network (U24 Clinical Trial Not Allowed) Apply for RFA AG 24 035 Funding Number: RFA AG 24 035 Agency: National Institutes of Health Category: Health Funding Amount: $385,000 |
| Kenya Digital Health Ecosystem Activity Apply for 72061523RFI00001 Funding Number: 72061523RFI00001 Agency: Kenya USAID-Nairobi Category: Health Funding Amount: $20,000,000 |
| Data Coordinating Center for Approaches to Identifying Preteen Suicide Risk and Protective Factors (U24 Clinical Trial Not Allowed) Apply for RFA MH 24 322 Funding Number: RFA MH 24 322 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) Apply for PAR 23 300 Funding Number: PAR 23 300 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Computational Models of Influenza Immunity (U01 Clinical Trial Not Allowed) Apply for RFA AI 23 056 Funding Number: RFA AI 23 056 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Human Virome Program: Characterization of functional interactions between viruses and human and microbial hosts (U01 Clinical Trial Not Allowed) Apply for RFA RM 23 017 Funding Number: RFA RM 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Consortium Organization and Data Collaboration Center (CODCC) for the Human Virome Program (HVP) (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 016 Funding Number: RFA RM 23 016 Agency: National Institutes of Health Category: Health Funding Amount: $1,875,000 |
| Human Virome Characterization Centers (U54 Clinical Trial Not Allowed) Apply for RFA RM 23 019 Funding Number: RFA RM 23 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) Apply for RFA RM 23 018 Funding Number: RFA RM 23 018 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Apply for PAR 23 305 Funding Number: PAR 23 305 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) Apply for PAR 23 307 Funding Number: PAR 23 307 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional) Apply for RFA MH 24 332 Funding Number: RFA MH 24 332 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required) Apply for RFA MD 24 003 Funding Number: RFA MD 24 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) Apply for PAR 23 301 Funding Number: PAR 23 301 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) Apply for PAR 23 302 Funding Number: PAR 23 302 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 054 Funding Number: RFA AI 23 054 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed) Apply for RFA DE 24 006 Funding Number: RFA DE 24 006 Agency: National Institutes of Health Category: Health Funding Amount: $650,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 24 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.